Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Metastatic Squamous Neck Cancer With Occult Primary

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Metastatic Squamous Neck Cancer With Occult Primary

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      unresolved
      derivation note
      Derived from NCI topic(s): Metastatic Squamous Neck Cancer With Occult Primary. Strongest NCIt resolution: unmatched. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      3 more-specific settings
      metastatic Metastatic Squamous Neck Cancer With Occult Primary →recurrent Metastatic Squamous Neck Cancer With Occult Primary →metastatic Metastatic Squamous Neck Cancer With Occult Primary →

      Study evidence for this setting

      9 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00095628 · Registry condition search · Scope: narrower

      SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00387335 · Registry condition search · Scope: narrower

      Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

      4 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT00507767 · Registry condition search · Scope: narrower

      Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      1 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00513435 · Registry condition search · Scope: narrower

      Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      2 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT00939627 · Registry condition search · Scope: narrower

      Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

      6 outcome links · 2 safety-group records · 1 quality-of-life measures

      →

      NCT01044433 · Registry condition search · Scope: narrower

      Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

      5 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT01806675 · Registry condition search · Scope: narrower

      18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

      5 outcome links · 3 safety-group records · 1 quality-of-life measures

      →

      NCT01816984 · Registry condition search · Scope: narrower

      PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT02644122 · Registry condition search · Scope: narrower

      SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes

      5 outcome links · 1 safety-group records · 1 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice